Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China ,Taiwan ,United States ,Hong Kong ,Suzhou ,Jiangsu ,Macau ,Chinese ,Adimab Incyte ,Michael Yu ,Eli Lilly ,Company Lilly ,Prnewswire Innovent Biologics Inc ,Company Forward ,Md Anderson Cancer Center ,China National Healthcare Security Administration ,National Reimbursement Drug List ,National Reimbursement Drugs List ,Incyte Corporation ,Healthy China ,General Manager ,Lilly China ,For China ,Min Liu ,Chief Commercial Officer ,Biologics License Application ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Innovent Biologic ,Mainland China ,Company Forward Looking ,Innovent Biologics ,